Optimizing Phlebotomy and Cytoreductive Therapy in PV
A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line therapy in patients with polycythemia vera (PV) requiring combined phlebotomy and cytoreductive treatment, focusing on hematocrit control, symptom improvement, phlebotomy frequency reduction, and molecular marker trends as key indicators of therapeutic efficacy.
Video content above is prompted by the following:
- Please discuss which clinical and laboratory parameters you find most valuable when assessing response to first-line therapy, particularly in patients with PV requiring both phlebotomy and cytoreductive therapy.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
